Profil bibliographique

Rodolfo F. Perini

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

244Publications signalées

16559Citations signalées

1Affiliations récentes

Institutions déclarées

Merck & Co., Inc., Rahway, NJ, USA (United States)

Domaines associés

Renal cell carcinoma treatmentCancer Immunotherapy and BiomarkersCancer, Hypoxia, and MetabolismBladder and Urothelial Cancer TreatmentsCancer Genomics and Diagnostics

Publications récentes

Accès ouvert 2026 articleOpenAlex

34 Belzutifan Plus Lenvatinib Versus Cabozantinib in Post–PD-(L)1 Renal Cell Carcinoma: Health-Related Quality-of-Life Outcomes in the Phase 3 LITESPARK-011 Study

Manuela Schmidinger, Daniel Y C Heng, Ray McDermott, Se Hoon Park et autres

0 citationsThe Oncologist

2026 articleOpenAlex

Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial

Robert J. Motzer, Ray McDermott, Se Hoon Park, Mauricio Burotto et autres

2 citationsThe Lancet

2026 conference-abstractOpenAlex

Belzutifan plus lenvatinib versus cabozantinib in post–PD-(L)1 renal cell carcinoma (RCC): Health-related quality-of-life (HRQoL) outcomes in the phase 3 LITESPARK-011 study.

Daniel Yick Chin Heng, Robert J. Motzer, Raymond S. McDermott, Se Hoon Park et autres

0 citationsJournal of Clinical Oncology

Accès ouvert 2026 conference-abstractOpenAlex

ctDNA analysis in participants with renal cell carcinoma treated with adjuvant pembrolizumab or placebo in the KEYNOTE-564 trial.

Toni K. Choueiri, Piotr Tomczak, Naomi B. Haas, David F. McDermott et autres

2 citationsJournal of Clinical Oncology

Accès ouvert 2026 conference-abstractOpenAlex

Extended follow-up (6 years) of the phase 2 LITESPARK-004 study of belzutifan in participants with von Hippel-Lindau disease–associated neoplasms.

Ramaprasad Srinivasan, Vivek Narayan, Othon Iliopoulos, Kathryn E. Beckermann et autres

0 citationsJournal of Clinical Oncology

Accès ouvert 2026 articleOpenAlex

Belzutifan efficacy in von Hippel-Lindau disease-associated renal cell carcinoma versus natural history control arm

W Marston Linehan, Thomas Jemielita, Jerry Cornell, K. Chen et autres

1 citationJNCI Journal of the National Cancer Institute

Accès ouvert 2026 articleOpenAlex

Belzutifan (bel) plus lenvatinib (lenva) versus cabozantinib (cabo) for advanced renal cell carcinoma (RCC) after anti–PD-(L)1 therapy: Open-label phase 3 LITESPARK-011 study.

R Motzer, Se Hoon Park, Raymond S. McDermott, C. Porta et autres

6 citationsJournal of Clinical Oncology

Accès ouvert 2026 conference-abstractOpenAlex

Biomarker analysis from the phase 2 LITESPARK-013 study of 2 different belzutifan (bel) doses in participants (pts) with advanced clear cell renal cell carcinoma (ccRCC).

Neeraj Agarwal, James Brugarolas, Pooja Ghatalia, Saby George et autres

2 citationsJournal of Clinical Oncology

Accès ouvert 2026 conference-abstractOpenAlex

Circulating tumor DNA (ctDNA) analysis in participants (pts) with advanced clear cell renal cell carcinoma (ccRCC) treated with first-line pembrolizumab (pembro) monotherapy from the phase 2 KEYNOTE-427 study.

David F. McDermott, S. Signoretti, J L Lee, Frede Donskov et autres

0 citationsJournal of Clinical Oncology

Accès ouvert 2026 conference-abstractOpenAlex

KEYMAKER-U03 substudy 03B: Novel investigative regimens for previously treated advanced clear cell renal cell carcinoma (ccRCC).

Laurence Albigès, Cristina Suárez, Kathryn E. Beckermann, Walter M. Stadler et autres

2 citationsJournal of Clinical Oncology

Accès ouvert 2026 conference-abstractOpenAlex

Ascending dose escalation of belzutifan plus palbociclib for previously treated advanced clear cell renal cell carcinoma (ccRCC): Phase 1/2 LITESPARK-024 study part 1.

David F. McDermott, A. Peer, Howard Gurney, Azim Khan et autres

1 citationJournal of Clinical Oncology

Accès ouvert 2026 articleOpenAlex

Real-world treatment patterns and clinical outcomes among patients with metastatic renal cell carcinoma post immune-oncology and vascular endothelial growth factor receptor targeted therapies: A multicenter community oncology-based study

Neil J. Shah, Sneha Sura, Reshma Shinde, Wei Dai et autres

0 citationsUrologic Oncology Seminars and Original Investigations

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.